Compare ADT Inc (ADT) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

ADT trades at $7.51, down 1.7% today, amid strong technical momentum with bullish moving averages and ADX signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.23 beating estimates of $0.22, and improving profitability with net margin reaching 11.86% in 2025. Recent news highlights ADT's Zacks upgrade to Buy and strong Q2 results with 18% operating cash flow growth.

ADT presents a compelling value opportunity with attractive valuation multiples (P/E 10.35, EV/EBITDA 4.93) and bullish analyst sentiment (47% Buy ratings). Key risks include high debt levels ($7.51B long-term debt) and competitive pressures in security services. The stock's technical strength and fundamental improvements support a positive near-term outlook, though investors should monitor debt management and industry competition.

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.